163 related articles for article (PubMed ID: 29449079)
1. Cost-Effectiveness of Ivabradine in the Treatment of Chronic Heart Failure.
Adena MA; Hamann G; Sindone AP
Heart Lung Circ; 2019 Mar; 28(3):414-422. PubMed ID: 29449079
[TBL] [Abstract][Full Text] [Related]
2. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective.
Griffiths A; Paracha N; Davies A; Branscombe N; Cowie MR; Sculpher M
Heart; 2014 Jul; 100(13):1031-6. PubMed ID: 24634022
[TBL] [Abstract][Full Text] [Related]
3. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial.
Bocchi EA; Rassi S; Guimarães GV;
ESC Heart Fail; 2018 Jun; 5(3):249-256. PubMed ID: 29266804
[TBL] [Abstract][Full Text] [Related]
4. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
[TBL] [Abstract][Full Text] [Related]
5. Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial.
Griffiths A; Paracha N; Davies A; Branscombe N; Cowie MR; Sculpher M
Adv Ther; 2017 Mar; 34(3):753-764. PubMed ID: 28205056
[TBL] [Abstract][Full Text] [Related]
6. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
Böhm M; Komajda M; Borer JS; Ford I; Maack C; Tavazzi L; Moyne A; Swedberg K;
Eur J Heart Fail; 2018 Feb; 20(2):373-381. PubMed ID: 29027329
[TBL] [Abstract][Full Text] [Related]
7. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
Borer JS; Deedwania PC; Kim JB; Böhm M
Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
[TBL] [Abstract][Full Text] [Related]
8. Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine.
Pereira-Barretto AC
Am J Cardiovasc Drugs; 2016 Apr; 16(2):93-101. PubMed ID: 26817946
[TBL] [Abstract][Full Text] [Related]
9. Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients.
Rogers JK; Kielhorn A; Borer JS; Ford I; Pocock SJ
Curr Med Res Opin; 2015; 31(10):1903-9. PubMed ID: 26361063
[TBL] [Abstract][Full Text] [Related]
10. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
[TBL] [Abstract][Full Text] [Related]
11. Effects of ivabradine therapy on heart failure biomarkers.
Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
[TBL] [Abstract][Full Text] [Related]
12. Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction.
Böhm M; Abdin A; Slawik J; Mahfoud F; Borer J; Ford I; Swedberg K; Tavazzi L; Batailler C; Komajda M
Eur J Heart Fail; 2023 Aug; 25(8):1429-1435. PubMed ID: 37092340
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.
Kourlaba G; Parissis J; Karavidas A; Beletsi A; Milonas C; Branscombe N; Maniadakis N
BMC Health Serv Res; 2014 Dec; 14():631. PubMed ID: 25496716
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Ivabradine for Heart Failure in the United States.
Kansal AR; Cowie MR; Kielhorn A; Krotneva S; Tafazzoli A; Zheng Y; Yurgin N
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27153871
[TBL] [Abstract][Full Text] [Related]
15. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study.
Borer JS; Böhm M; Ford I; Komajda M; Tavazzi L; Sendon JL; Alings M; Lopez-de-Sa E; Swedberg K;
Eur Heart J; 2012 Nov; 33(22):2813-20. PubMed ID: 22927555
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
[TBL] [Abstract][Full Text] [Related]
17. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
[TBL] [Abstract][Full Text] [Related]
18. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
Ekman I; Chassany O; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L; Swedberg K
Eur Heart J; 2011 Oct; 32(19):2395-404. PubMed ID: 21875859
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness and budget impact of ivabradine in heart failure therapy].
Polistena B; Maggioni AP; Oliva F; Spandonaro F
G Ital Cardiol (Rome); 2014 Nov; 15(11):626-33. PubMed ID: 25424141
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
